Latest Production News

SGH Ltd and Steel Dynamics have jointly submitted a best and final offer of A$32.35 per share to acquire BlueScope Steel, valuing the company at A$15 billion and representing a significant premium over recent trading prices.

Magellan Financial Group reported a 27% drop in statutory net profit but maintained stable operating profit and increased earnings per share by 5%, supported by ongoing share buybacks. The company declared a fully franked interim dividend up 50%, reflecting confidence despite investment performance challenges.

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

Nelson Resources has identified high-grade gold and silver mineralisation in intrusion-hosted veins at its Gold Point Project in Nevada, with rock chip samples reaching up to 15.1g/t gold. The discovery expands the known mineralised footprint and sets the stage for maiden drilling in Q2 2026.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

Step One Clothing reports a sharp revenue decline and a significant inventory write-down, posting a net loss in the first half of 2026. The company signals a strategic reset to regain momentum.

Netwealth Group Limited has reported a robust first half of FY26, with record funds under administration and a significant increase in dividends, underpinned by strong inflows and strategic technology investments.

SHAPE Australia Corporation Limited has reported a robust first half of FY26, with significant gains in revenue, profits, and project pipeline, underpinned by strategic sector diversification and a key acquisition.

SHAPE Australia Corporation Limited reported a robust half-year performance with a 48.5% rise in net profit and declared a fully franked 14 cent interim dividend, underpinned by strategic acquisition and operational discipline.

Euro Manganese Inc. reported progress on its Chvaletice and Bécancour manganese projects, securing funding amendments and advancing permitting despite ongoing financial pressures. The company is positioned to benefit from growing demand for high-purity manganese in lithium-ion batteries amid evolving market dynamics.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

Euro Manganese Inc. reported a net loss of $3.6 million for Q3 2025 and extended key financing milestones to June 2026, highlighting ongoing challenges in funding its Chvaletice Manganese Project.